Skip to Content
Search Menu

EHA24: New Treatment Regimen Marks a Breakthrough for Patients with Multiple Myeloma

The use of Isa-VRd as a new standard-of-care option for frontline disease control in patients aged ≤80 with transplant-ineligible NDMM.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Relateret indhold

Several Trials Showed Improvements in the Treatment of Multiple Myeloma

/ BestPractice Nordic
EHA24Myeloma

EHA 2024: One of the Most Important for Many Years

/ BestPractice Nordic
EHA24Lymphoma

CLL: Needs At Least 10 Years of Follow-Up for Clinical Trials

/ BestPractice Nordic
CLLEHA24

The Development of New Treatment Options within AML Is Slower Than in Other Disease Areas within Hematology

/ BestPractice Nordic
AMLEHA24

Using PRO Data to Assess Treatment Readiness in Multiple Myeloma

/ Tine Rosenberg / Thomas Lund / Jannie Kirkegaard
Myelooma

New Data from EHA Shared and Discussed at Danish Evening

/ Jan Andreasen
EHA24
Fredrik Schjesvold

Choice of Selinexor in the Treatment of Myeloma

/ Fredrik Schjesvold
Myelooma Play the Video 7:09
Maria Eugenia Chollet

Promising Avenues for the Development of Personalized Treatment for FVII Deficiency

/ Maria Eugenia Chollet
EHA24 Play the Video 5:06
Hanne Norseth

Vaccinating Against Mutated RAS in Multiple Myeloma

/ Hanne Norseth
EHA24Myeloma Play the Video 3:27
Back to top